Immunotherapies
have evolved
Harnessing more of the immune system for better cancer outcomes
Latest News

Gilead statement on the @NEJM publication of data from the NIAID study of our investigational antiviral drug to treat COVID-19: https://bit.ly/2Zts19B.

https://www.aacr.org/about-the-aacr/newsroom/news-releases/dr-steven-a-rosenberg-recognized-with-the-2020-aacr-cri-lloyd-j-old-award-in-cancer-immunology/?utm_medium=linkedin&utm_source=social&utm_campaign=pressrelease&utm_content=lloydaward&sf122097145=1

Very well deserved. From the @oNKo_innate team, a huge congratulations to Steven Rosenberg @NIH, a pioneer in immune cell therapy on the @CancerResearch Lloyd J Old award for 2020

Load More...
 
Discover oNKo-innate
With our deep understanding of Natural Killer (NK) cells, we aim to be the first to master NK cell biology and therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.
Learn more
OUR APPROACH
Using powerful genomic approaches, we screen primary immune cells and cancer cells to understand their interaction within a tumor.
Learn more
lab1-webRes
o o
o
THE TEAM
We are driven by the challenge of engaging the immune system to fight cancer, and focused on delivering the first truly effective NK cell immunotherapies.
Find out who we are